CELZ
Creative Medical Technology Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.11
+4.72%Aug 20, 2026, 13:15 UTC
Creative Medical Technology Holdings completed enrollment and treatment of all patients across its FDA-cleared ADAPT clinical trial for CELZ-201/Olastrocel, including the opioid expansion cohort, advancing the therapy toward RMAT evaluation and Phase 3 planning for chronic lower back pain.
Source:Jul 2, 2026, 00:00 UTC
Creative Medical Technology Holdings issued new inducement warrants to purchase 5,580,680 common shares at $1.60 per share after holders exercised existing warrants for aggregate gross proceeds of approximately $4.5 million.
Source:Jun 25, 2026, 21:57 UTC
Creative Medical Technology Holdings, Inc. filed for a securities offering.
Source:Jun 16, 2026, 19:52 UTC
Creative Medical Technology Holdings Inc opened a nationwide virtual data-collection registry for Project PHOENIX to support U.S. veterans exposed to burn pits.
Source: